Takeda files reply in support of decertifying class in US Amitiza antitrust case
MLex Summary: Takeda Pharmaceuticals filed a reply in support of its motion to decertify a class of direct purchasers accusing it of delaying a generic version of the drug Amitiza. “DPPs...To view the full article, register now.
Already a subscriber? Click here to view full article